Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
-
Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference
-
Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference
-
Neoleukin Therapeutics (NLTX) Prices 3.26M Share Common Offering at $15.25/Sh
-
Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering
-
Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering
-
Neoleukin Therapeutics (NLTX) Announces 5M Share Proposed Public Offering
-
Neoleukin Therapeutics Announces Proposed Public Offering
-
Neoleukin Therapeutics Announces Proposed Public Offering
-
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Neoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh
-
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
-
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
-
Neoleukin Therapeutics (NLTX) Announces Proposed $50M Public Offering of Common Stock
-
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
-
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
